Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
1.38 (USD) • At close September 4, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 1.436 | 1.697 |
| Cost of Revenue
| 0.178 | 42.318 | 0.169 | 0.004 | 7.997 | 0.009 |
| Gross Profit
| -0.178 | -42.318 | -0.169 | -0.004 | -6.561 | 1.688 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | -4.569 | 0.995 |
| Reseach & Development Expenses
| 93.798 | 42.318 | 32.36 | 12.305 | 7.997 | 8.576 |
| General & Administrative Expenses
| 20.219 | 18.82 | 12.876 | 7.279 | 1.351 | 0.926 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 20.219 | 18.82 | 12.876 | 7.279 | 1.351 | 0.926 |
| Other Expenses
| 0 | 0 | 0.001 | 0 | -7.997 | 0 |
| Operating Expenses
| 114.017 | 61.138 | 45.237 | 19.584 | 1.351 | 9.502 |
| Operating Income
| -114.017 | -61.138 | -45.237 | -19.584 | -7.912 | -7.805 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | -5.51 | -4.599 |
| Total Other Income Expenses Net
| 11.688 | 8.767 | 2.381 | -81.022 | 0.587 | -0.102 |
| Income Before Tax
| -102.329 | -52.371 | -42.856 | -100.606 | -7.325 | -7.907 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | -5.101 | -4.659 |
| Income Tax Expense
| 0 | 0 | 0 | 0 | 0 | -0.045 |
| Net Income
| -102.329 | -52.371 | -42.856 | -100.606 | -7.325 | -7.907 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | -5.101 | -4.659 |
| EPS
| -1.71 | -1.08 | -1.06 | -2.63 | -0.26 | -0.2 |
| EPS Diluted
| -1.71 | -1.08 | -1.06 | -2.63 | -0.26 | -0.27 |
| EBITDA
| -98.083 | -51.606 | -42.687 | -19.58 | -7.912 | 0.119 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | -5.51 | 0.07 |